Brain Cancer Therapeutics Market Size, Share & Industry Analysis, By Type(Gliomas, Meningiomas, Pituitary Adenomas, Vestibular Schwannomas, Neuroectodermal Tumors), By Treatment (Chemotherapy, Immunotherapy, Targeted Drug Therapy, Radiation Therapy, Others) and Regional Forecast, 2024-2032

In May 2019, Australian company Kazia Therapeutics collaborated with the “Alliance for Clinical Trials in Oncology Foundation” on clinical trials for metastatic brain cancer treatment. Brain cancer is referred as the growth of abnormal cells in the brain. Some are non-cancerous or benign, and some are cancerous or malignant. The exact cause of brain cancer is not known; however, some of the identified factors that may increase the risk of brain cancer are exposure to ionizing radiation or the family history of brain tumour. The signs and symptoms of a brain tumour vary greatly and depend on the brain tumour’s size, location and rate of growth. The general symptoms include headache, gradual loss of sensation, difficulty in balance, speech difficulties, hearing problems. The treatment for brain cancer depends upon the type, size and location of the tumour. The main treatments are surgery, radiotherapy, chemotherapy, radiosurgery, and carmustine implants.

Factors such as the rising prevalence of brain cancer, growing research activities for developing novel treatments and increased government funding for brain cancer treatment research are expected to drive the growth of the global brain cancer therapeutics market during the forecast period. However, the high cost of the therapeutics, adverse side effects associated with cancer treatment medications, are projected to hamper the market growth during the forecast period.

Key Players Covered:

Some of the major companies that are present in the brain cancer therapeutics market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, Eisai Co. Ltd., Pfizer Inc., Bayer AG, and others.

Key Insights

• Prevalence of brain cancer for key countries or key regions


• New product launches in brain cancer therapeutics market


• Technological advancements in global brain cancer therapeutics market


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis:

North America is projected to dominate the global brain cancer therapeutics market over the forecast period, followed by Europe. The dominance of North America is mainly attributed to the developed healthcare infrastructure, rising awareness regarding the adoption of advanced technologies among the patients and the presence of a large patient population. On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period.

Increasing accessibility to healthcare facilities, evolving healthcare infrastructure and the large population suffering from brain cancer are the factors projected to drive the growth of the market in the Asia Pacific region. Latin America and Middle East America are also expected to have substantial growth in the brain cancer therapeutics market during the forecast period.

Segmentation

Brain Cancer Therapeutics Industry Developments     

• In April 2019, Mateon Therapeutics, Inc. merged with Oncotelic Inc. to focus on pipeline of TGF-β RNA therapeutics for late stage cancers, including gliomas and melanoma.


• In May 2019, China Anti-Cancer Association launched Optune, a cancer therapy that uses electric fields to disrupt cell division which inhibits tumour growth.


• In November 2018, Department of Radiation Oncology, Germany launched intensity-modulated radiotherapy (IMRT) which allows the delivery of higher radiation doses to the target volume and at the same time reduces the risk of toxicity to normal tissues as compared with conventional 3D conformal radiotherapy (3D-CRT).